公开(公告)号：WO2021151442A2

公开(公告)日：2021-08-05

申请号：PCT/DK2021/050025

申请日：2021-01-26

Applicant: ROS THERAPEUTICS APS

Inventor： HØJGAARD, Bent ,  DAMGAARD JENSEN, Hanne

IPC: A61K9/20 ,  A61K9/48 ,  A61K31/519 ,  A61P17/06 ,  A61P19/02 ,  A61P35/02 ,  A61K9/28 ,  A61K9/2072 ,  A61K9/2866 ,  A61K9/4808 ,  A61K9/5047 ,  A61K9/5084

Abstract: The present invention relates to a pharmaceutical dosage form comprising an active ingredient such as methotrexate or a pharmaceutically acceptable salt thereof, in particular in the form of pellets, such as multiparticulates, mini-tablets or granulate. It further relates to oral dosage forms for which saturation kinetics limits the oral use of higher dosages of active ingredients.

公开(公告)号：WO2021191268A1

公开(公告)日：2021-09-30

申请号：PCT/EP2021/057555

申请日：2021-03-24

Applicant: INIBSA GINECOLOGÍA, S.A.

Inventor： SAURA I VALLS, Marc ,  NEBOT TROYANO, Joaquín ,  ROCA I JUANES, Ramon M. ,  MALDONADO VILLEGAS, Adrià ,  COLOMBO, Giuseppe

IPC: A61K9/50 ,  A61K31/4402 ,  A61K31/4415 ,  A61K9/48 ,  A61K9/5026 ,  A61K9/5063 ,  A61K9/5078 ,  A61K9/5084 ,  A61K9/5089

Abstract: A modified release multiple unit oral dosage form of doxylamine succinate and pyridoxine hydrochloride and a process for its preparation The present invention relates to modified release multiple unit oral dosage form comprising: a first plurality of modified release pellets of doxylamine comprising: a pharmaceutically acceptable inert nucleus; an inner active coating layer comprising a doxylamine; optionally an intermediate enteric release coating layer; and an external modified release coating layer; and a second plurality of modified release pellets of pyridoxine or a pharmaceutically acceptable salt thereof comprising: a pharmaceutically acceptable inert nucleus; an inner active coating layer comprising pyridoxine or a pharmaceutically acceptable salt thereof; and an external modified release coating layer; wherein the particle size of the pharmaceutically acceptable inert nucleus of the first and the second plurality of pellets is such that at least 90% of the inert nuclei have a particle size from 300 µm to 1700 µm and a particle size variability of not more than200 µm measured by analytical sieving. It also relates to a process for its preparation and its use in therapy.

公开(公告)号：WO2021260211A1

公开(公告)日：2021-12-30

申请号：PCT/EP2021/067583

申请日：2021-06-25

Applicant: BAUSCH HEALTH IRELAND LIMITED

Inventor： COLE, Jacob ,  ROHRS, Brian R. ,  STEIN, Daniel J. ,  ISRAEL, Robert J. ,  LOWE, Ezra R.

IPC: A61K9/50 ,  A61K31/437 ,  A61K45/06 ,  A61K9/1676 ,  A61K9/5026 ,  A61K9/5078 ,  A61K9/5084 ,  A61P1/00

Abstract: Provided herein are GI specific rifaximin release compositions which can be formulated for targeted delivery of rifaximin to one or more portions of the GI tract. Methods of treating diseases and disorders with the disclosed compositions are also provided.

公开(公告)号：WO2021231350A1

公开(公告)日：2021-11-18

申请号：PCT/US2021/031675

申请日：2021-05-11

Applicant: MASSACHUSETTS INSTITUTE OF TECHNOLOGY

Inventor： LANGER, Robert S. ,  JAKLENEC, Ana ,  LU, Xueguang

IPC: A61K9/00 ,  A61K9/50 ,  A61K31/7084 ,  A61P35/00 ,  A61K31/519 ,  A61K31/7088 ,  A61K45/06 ,  A61K47/6937 ,  A61K9/0019 ,  A61K9/0021 ,  A61K9/5031 ,  A61K9/5084 ,  A61K9/5089 ,  B82Y40/00 ,  B82Y5/00 ,  C07K16/2818 ,  C07K16/2827

Abstract: Microparticulate compositions and methods for delivery and pulsatile release of one or more sting agonists and/or receptors have been developed. The compositions include polymeric microdevices formed from biodegradable and biocompatible polymers or co-polymers thereof including a shell and compartment(s) or discrete regions in the compartment(s) formed by an additive process such as micromolding, three-dimensional printing and lithography. The compositions include microdevices that release individual doses of incorporated STING agonist and/or receptors at defined times, for example, in pulses up to several months after administration with essentially no leakage between releases.

公开(公告)号：WO2023057451A1

公开(公告)日：2023-04-13

申请号：PCT/EP2022/077586

申请日：2022-10-04

Applicant: HERMES PHARMA GMBH

Inventor： WEISS, Gerd ,  HAALA, Josef ,  SCHIEMENZ, Wolfgang

IPC: A61K9/50 ,  A61K33/06 ,  A61K9/00 ,  A23L33/16 ,  A61K9/0056 ,  A61K9/5015 ,  A61K9/5084 ,  A61K9/5089

Abstract: Erfindungsgemäß wird ein orales Direktgranulat, welches eine kontrollierte Magnesium-Freisetzung mit sowohl retardierten als auch nicht-retardierten Anteilen ermöglicht. Das Granulat enthält unter anderem Retardpartikel mit einem magnesiumhaltigen Kern und einem lipophilen Überzug, wobei mindestens die Kerne dieser Retardpartikel eine vorgegebene Abriebfestigkeit aufweisen, welche mittels Vibrationssiebung über einen Zeitraum von 60 Minuten bestimmt wird und welche eine Schmelzbeschichtung dieser Kerne ermöglicht, insbesondere eine Schmelzbeschichtung mit Lipiden in der Wirbelschicht. Die Erfindung stellt ferner eine Methode zur Charakterisierung der Magnesium-haltigen Kerne bereit, sowie ein Verfahren zur Herstellung der Retardpartikel mittels Schmelzbeschichtung (Hot-Melt-Coating).

公开(公告)号：WO2022024126A2

公开(公告)日：2022-02-03

申请号：PCT/IL2021/050914

申请日：2021-07-29

Applicant: KARNAK TECHNOLOGIES, LLC ,  EZRA, Rafael

Inventor： EZRA, Rafael

IPC: A61K9/00 ,  A61K9/16 ,  A61K9/50 ,  A23L29/206 ,  A23L29/262 ,  A23L29/30 ,  A23L33/10 ,  A23L33/30 ,  A23P10/35 ,  A23P10/47 ,  A61K31/01 ,  A61K31/05 ,  A61K31/352 ,  A61K31/593 ,  A61K36/185 ,  A61K36/53 ,  A61K9/1623 ,  A61K9/1652 ,  A61K9/1664 ,  A61K9/1694 ,  A61K9/19 ,  A61K9/5015 ,  A61K9/5084

Abstract: The invention provides compositions that increase oral bioavailability of edible lipophilic substances such as beneficial edible oils, oil-soluble vitamins, and nutraceuticals. The compositions and methods of the invention are highly applicable to food industries in the production of foods, beverages, supplements, and food additives.